Anti-PD-1 Antibodies, Fusion Proteins, Kadmon, Granted 28th Apr
Summary
USPTO granted Patent US12612460B2 to Kadmon Corporation, LLC on April 28, 2026, covering recombinant anti-PD-1 antibodies, antigen-binding fragments, and fusion proteins useful for inhibiting programmed death 1 (PD-1). The patent contains 19 claims and names six inventors including Dan Lu, Zhanna Polonskaya, and Jeegar P. Patel. The invention encompasses nucleic acid molecules encoding the antibodies and therapeutic compositions for treating immune dysfunction-related disorders including cancer and infectious diseases.
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
USPTO issued Patent US12612460B2 (Kind B2) to Kadmon Corporation, LLC on April 28, 2026, covering recombinant anti-PD-1 antibodies and fusion proteins. The patent names six inventors and contains 19 claims spanning CPC classifications C07K 14/5443 and A61K 40/36.
For biotechnology and pharmaceutical companies developing PD-1/PD-L1 pathway therapeutics, this patent establishes intellectual property coverage that may affect freedom-to-operate analyses for competing programs. Companies should review their product pipelines for potential overlap with the claims scope, which covers methods for enhancing T cell and NK cell function and treatment of immune dysfunction disorders.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Anti-PD-1 antibodies and fusion proteins
Grant US12612460B2 Kind: B2 Apr 28, 2026
Assignee
Kadmon Corporation, LLC
Inventors
Dan Lu, Zhanna Polonskaya, Tzu-Pei Chang, Stella Aviaty Martomo, Jeegar P. Patel, Faical Miyara
Abstract
Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.
CPC Classifications
C07K 14/5443 A61K 40/36
Filing Date
2024-12-20
Application No.
18989801
Claims
19
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.